Paper37554517
Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex.
Tollenaere MAX and 6 others. JID Innov, 2023. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex. Papers, record 37554517. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37554517
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27956146 | Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2. | J Mol Biol | 2017 | https://conductscience.org/library/papers/27956146 | PubMed |
| 2 | 12642601 | Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. | J Exp Med | 2003 | https://conductscience.org/library/papers/12642601 | PubMed |
| 3 | 31230370 | Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. | Allergy | 2020 | https://conductscience.org/library/papers/31230370 | PubMed |
| 4 | 29772180 | Determination of Affinity and Residence Time of Potent Drug-Target Complexes by Label-free Biosensing. | J Med Chem | 2018 | https://conductscience.org/library/papers/29772180 | PubMed |
| 5 | 9013879 | Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. | FEBS Lett | 1997 | https://conductscience.org/library/papers/9013879 | PubMed |
| 6 | 20223216 | Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. | Structure | 2010 | https://conductscience.org/library/papers/20223216 | PubMed |
| 7 | 8552669 | Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. | Proc Natl Acad Sci U S A | 1996 | https://conductscience.org/library/papers/8552669 | PubMed |
| 8 | 28660216 | Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis. | J Immunol Res | 2017 | https://conductscience.org/library/papers/28660216 | PubMed |
| 9 | 12354755 | Kinetic analysis of the interleukin-13 receptor complex. | J Biol Chem | 2002 | https://conductscience.org/library/papers/12354755 | PubMed |
| 10 | 18243101 | Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. | Cell | 2008 | https://conductscience.org/library/papers/18243101 | PubMed |
| 11 | 11786536 | A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha -2 and their rapid mobilization by interferon-gamma. | J Biol Chem | 2002 | https://conductscience.org/library/papers/11786536 | PubMed |
| 12 | 12642602 | Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. | J Exp Med | 2003 | https://conductscience.org/library/papers/12642602 | PubMed |
| 13 | 31397016 | Chitinase 3-like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation. | Clin Exp Allergy | 2019 | https://conductscience.org/library/papers/31397016 | PubMed |
| 14 | 17030238 | IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts. | J Allergy Clin Immunol | 2006 | https://conductscience.org/library/papers/17030238 | PubMed |
| 15 | 12642599 | Decoy receptors in the regulation of T helper cell type 2 responses. | J Exp Med | 2003 | https://conductscience.org/library/papers/12642599 | PubMed |
| 16 | 16327802 | IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. | Nat Med | 2006 | https://conductscience.org/library/papers/16327802 | PubMed |
| 17 | 31838750 | Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. | Allergy | 2020 | https://conductscience.org/library/papers/31838750 | PubMed |
| 18 | 21622864 | IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2. | J Immunol | 2011 | https://conductscience.org/library/papers/21622864 | PubMed |
| 19 | 8910586 | cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. | J Biol Chem | 1996 | https://conductscience.org/library/papers/8910586 | PubMed |
| 20 | 33000465 | Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). | Br J Dermatol | 2021 | https://conductscience.org/library/papers/33000465 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42825999 | Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/42825999 | PubMed |
| 42702765 | Real-World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis. | Clin Transl Allergy | 2026 | https://conductscience.org/library/papers/42702765 | PubMed |
| 42459660 | Immunomodulatory effects of nematode-microbiota interactions in cancer therapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42459660 | PubMed |
| 42360589 | A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'". | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/42360589 | PubMed |
| 42033591 | Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/42033591 | PubMed |
| 41642555 | Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/41642555 | PubMed |
| 40767793 | Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action. | J Invest Dermatol | 2025 | https://conductscience.org/library/papers/40767793 | PubMed |
| 40721559 | Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16. | Dermatol Ther (Heidelb) | 2025 | https://conductscience.org/library/papers/40721559 | PubMed |
| 40418285 | Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations. | Am J Clin Dermatol | 2025 | https://conductscience.org/library/papers/40418285 | PubMed |
| 40085349 | Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years. | Am J Clin Dermatol | 2025 | https://conductscience.org/library/papers/40085349 | PubMed |
| 39820896 | Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment. | Am J Clin Dermatol | 2025 | https://conductscience.org/library/papers/39820896 | PubMed |
| 39673366 | Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels. | Allergy | 2025 | https://conductscience.org/library/papers/39673366 | PubMed |
| 39385749 | Type 2 Cytokine-Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study. | JID Innov | 2025 | https://conductscience.org/library/papers/39385749 | PubMed |
| 39122503 | Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab. | Dermatol Pract Concept | 2024 | https://conductscience.org/library/papers/39122503 | PubMed |
| 38398754 | Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma. | Life (Basel) | 2024 | https://conductscience.org/library/papers/38398754 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACTB | 60 | PubTator's text mining | https://conductscience.org/library/genes/60 | NCBI Gene |
| CHI3L1 | 1116 | PubTator's text mining | https://conductscience.org/library/genes/1116 | NCBI Gene |
| IL13 | 3596 | PubTator's text mining | https://conductscience.org/library/genes/3596 | NCBI Gene |
| IL13RA1 | 3597 | PubTator's text mining | https://conductscience.org/library/genes/3597 | NCBI Gene |
| IL13RA2 | 3598 | PubTator's text mining | https://conductscience.org/library/genes/3598 | NCBI Gene |
| IL4 | 3565 | PubTator's text mining | https://conductscience.org/library/genes/3565 | NCBI Gene |
| IL4R | 3566 | PubTator's text mining | https://conductscience.org/library/genes/3566 | NCBI Gene |
| PPIA | 5478 | PubTator's text mining | https://conductscience.org/library/genes/5478 | NCBI Gene |
| RPLP0 | 6175 | PubTator's text mining | https://conductscience.org/library/genes/6175 | NCBI Gene |
| STAT6 | 6778 | PubTator's text mining | https://conductscience.org/library/genes/6778 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37554517
GET https://conductscience.org/api/papers/v1/37554517/references?page=2